摘要
目的 探讨无抽搐电休克治疗(MECT)联合阿戈美拉汀对抑郁症患者的效果.方法 选取 2021 年 6月—2022 年6 月收治的104 例抑郁症,根据治疗方法不同分为观察组和对照组各52 例,对照组予阿戈美拉汀治疗,观察组予MECT联合阿戈美拉汀治疗,疗程均为4 周.比较2 组疗效,治疗前后汉密尔顿抑郁量表(HAMD-24)评分、匹兹堡睡眠质量指数(PSQI)评分、自伤行为及C反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-18(IL-18)、肿瘤坏死因子-α(TNF-α)水平和不良反应.结果 治疗4 周后,观察组总有效率(92.31%,48/52)高于对照组(75.00%,39/52)(P＜0.05).2 组治疗2 周后、治疗4 周后HAMD-24 评分、PSQI评分、自伤行为方式、自伤行为频率及CRP、IL-18、TNF-α、IL-6 水平均低于或少于治疗前,且治疗4 周后低于或少于治疗 2 周后(P＜0.05);观察组治疗 2 周后、治疗 4周后HAMD-24 评分、PSQI评分、自伤行为方式、自伤行为频率及CRP、IL-18、TNF-α、IL-6 水平低于或少于对照组(P＜0.05).2 组不良反应总发生率比较差异无统计学意义(P＞0.05).结论 MECT联合阿戈美拉汀治疗可调控抑郁症患者炎性因子水平,降低患者抑郁程度及减少自伤行为,改善睡眠质量,且效果可靠、不良反应少.
Abstract
Objective To observe the effect of non-convulsive electroconvulsive therapy(MECT)combined with Ag-omelatine on patients with depression.Methods A total of 104 patients with depression admitted from June 2021 to June 2022 were divided into observation group(n =52)and control group(n =52)according to different treatment methods.The control group was treated with Agomelatine,and the observation group was treated with MECT combined with Agomelatine.The course of treatment was 4 weeks.The therapeutic effects,Hamilton depression scale(HAMD-24)score,Pittsburgh sleep quality index(PSQI)score,non-suicidal self-injury(NSSI)behavior,C-reactive protein(CRP),interleukin-6(IL-6),interleukin-18(IL-18),tumor necrosis factor-α(TNF-α)level and adverse reactions before and after treatment of the two groups were com-pared.Results At 4 weeks after treatment,the total effective rate of observation group was higher than that of control group[(92.31%,48/52)vs.(75.00%,39/52)](P＜0.05).HAMD-24 score,PSQI score,NSSI behavior pattern,frequency of NSSI behavior and levels of CRP,IL-18,TNF-α and IL-6 in the two groups were lower or less at 2 weeks and 4 weeks after treatment,and lower or less at 4 weeks after treatment,as compared with those at 2 weeks after treatment(P＜0.05).HAMD-24 score,PSQI score,NSSI behavior pattern,frequency of NSSI behavior,and CRP,IL-18,TNF-α and IL-6 levels in observation group were lower or less than those in control group at 2 weeks and 4 weeks after treatment(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion MECT combined with Agomelatine can regulate the levels of inflammatory factors in patients with depression,reduce the degree of de-pression and self-injury behavior,and improve sleep quality,and the effect is reliable with fewer adverse reactions.
国家科技期刊平台
NSTL
万方数据